H. Lundbeck (LUN) Investor update summary

Strategic positioning and market opportunity

• Focused exclusively on neuroscience, addressing a $160bn market potential by 2030 with a mission to advance brain health and transform lives.

• Neuroscience is among the fastest growing areas in medicine, with a 10% CAGR and significant unmet needs across brain disorders.

• The pipeline is aligned with high-growth neuro-rare and neuro-specialty segments, expanding faster than psychiatry.

Leadership and transformation

• A new, diverse executive leadership team with deep experience in global pharma and biotech is driving transformation and innovation.

• The strategy is a self-funded transition through loss of exclusivities, focusing on innovation-led growth and sustainable profitability.

Growth and financial performance

• Achieved strong revenue growth, with a 5-8% CAGR and a structural shift toward pipeline-driven growth post-2027.

• Strategic brands like Vyepti and Rexulti are driving accelerating revenue, with Vyepti positioned as a leading migraine therapy and Rexulti expanding via new indications.

• Disciplined capital reallocation and operational effectiveness have improved profitability, with EBITDA margin rising to over 30% by 2025.